Inactive Instrument

Highlights BioTime, Inc. Nyse

Equities

End-of-day quote Nyse Other stock markets
- ^USD	-

21/05	Lineage Cell Therapeutics, Inc. Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium	CI
09/05	Transcript : Lineage Cell Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lineage Cell Therapeutics, Inc. Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium	21/05	CI
Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Reports Q1 Revenue $1.4M, vs. Street Est of $1.36M	10/05	MT
Lineage Cell Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Lineage Cell Therapeutics, Inc. Announces 24 Month Visual Acuity Results Featured At 2024 Retinal Cell & Gene Therapy Innovation Summit	06/05	CI
Lineage Cell Therapeutics, Inc. Announces Preclinical Engraftment Results to Be Presented At 2024 Association for Research in Vision and Ophthalmology Meeting	11/03	CI
Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Reports Q4 Revenue $8.9M, vs. Street Est of $2.8M	08/03	MT
Lineage Announces FDA Clearance of IND Amendment for Opc1 Cell Transplant for the Treatment of Spinal Cord Injury	13/02	CI
Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury	18/12	CI
Lineage Cell Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Posts Q3 Revenue $1.2M, vs. Street Est of $2.6M	10/11	MT
Lineage Cell Therapeutics, Inc. Announces to Present Rg6501 Phase 1/2A Results to Be Featured At Eyecelerator At 2023 American Academy of Ophthalmology	24/23/24	CI
Lineage Cell Therapeutics, Inc. Announces Results of Imaging Analyses Demonstrating Rapid Improvement in Outer Retinal Structure from Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration	16/23/16	CI
Lineage Cell Therapeutics, Inc. Announces Results of Imaging Analyses Demonstrating Rapid Improvement in Outer Retinal Structure from Patients Enrolled in A Phase 1/2A Clinical Study of RG6501	05/23/05	CI
EARNINGS: R&Q Insurance loss swells, Jade Road still selling assets	29/23/29	AN
Lineage Cell Therapeutics, Inc. Announces the Results of Imaging Analyses Demonstrating Evidence of Rapid Improvement in Outside Retinal Structure from A Phase 1/2A Clinical Study of Rg6501	13/23/13	CI
Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Reports Q2 Revenue $3.2M, vs. Street Est of $2.2M	11/23/11	MT
Lineage Cell Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Lineage Cell Therapeutics and Cancer Research UK Reports Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer	24/23/24	CI
Lineage Cell Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Reports Q1 Revenue $2.4M, vs. Street Est of $2.01M	12/23/12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BioTime, Inc. Nyse

Equities

Highlights

Filters